chufangao/CTO huggingface dataset:
Clinical trial NCT02203604: High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
Official title: A Phase II Single Arm Study of High-Dose IL-2 and Ipilimumab in Patients With Unresectable Stage III and Stage IV Melanoma
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient rate of accrual
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-11-26
Primary completion date: 2020-01-27
Completion date: 2020-01-27
Limitations and caveats: The trial was closed early due to slow accrual. Early termination lead to a small number of subjects analyzed.
Plan to share individual participant data: NO
Clinical trial NCT04566133: Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Official title: Phase II Study of Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-02-15
Primary completion date: 2022-05-11
Completion date: 2022-12-31
Plan to share individual participant data: YES
IPD sharing description: All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).
IPD time frame: Clinical data available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing Plan (GDS) plan for as long as database is active.
IPD access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Clinical trial NCT02183805: Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Official title: Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therapy for Metastatic Triple-negative Breast Cancer
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulty accruing subjects the study accrual was closed
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-06-17
Primary completion date: 2020-12-15
Completion date: 2020-12-15
Plan to share individual participant data: NO
Clinical trial NCT01776424: Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
Official title: A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).
Acronym: COMPASS
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 27395.0 (ACTUAL)
Number of arms: 3.0
Start date: 2013-02-28
Primary completion date: 2017-07-21
Completion date: 2021-06-15
Baseline population: Intent-to-treat analysis set (ITT): included all participants randomized to antithrombotic treatment for the initial study part. The ITT set comprised both participants randomized to pantoprazole/placebo and participants not randomized to pantoprazole/placebo.
Limitations and caveats: One participant that was included in the Safety Analysis Set in the disclosure after primary completion never took any study drug therefore was corrected in the later analysis.
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access.~As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT03075241: Z-Drugs for Sleep Disorders in Alzheimer's Disease
Official title: Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Triple-blind, Placebo-controlled Study
Sponsor: Brasilia University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 62.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-10-31
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Plan to share individual participant data: NO
Clinical trial NCT04230213: A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
Official title: A RANDOMIZED COMPARATIVE STUDY ASSESSING THE SWITCHING BETWEEN PF-06410293 AND HUMIRA (REGISTERED) IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 455.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-13
Primary completion date: 2021-06-22
Completion date: 2021-06-22
Baseline population: Baseline analysis population included all the participants who were enrolled in TP1.
Limitations and caveats: In participant flow, there were discontinuations due to AEs, which were captured within different reasons for discontinuations (e.g. other, physician decision etc.) as the study case report form (CRF) page did not include AE as an option for sites to record if the discontinuation was truly due to AE.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04591444: Fluoride Varnish X Glass Ionomer Sealant on Cervical Dentin Hypersensitivity
Official title: Efficacy of a Fluoride Varnish and a Glass Ionomer Sealant on Cervical Dentin Hypersensitivity: A Randomized Clinical Trial
Sponsor: University of Sao Paulo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 121.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-01-31
Primary completion date: 2019-10-31
Completion date: 2020-03-31
Clinical trial NCT02899702: Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
Official title: Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial
Acronym: IGHN2
Sponsor: Hospices Civils de Lyon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: no EC approval obtained
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2024-09-30
Completion date: 2024-09-30
Plan to share individual participant data: NO
Clinical trial NCT03149120: Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
Official title: Phase II Randomized Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas After One Prior Line of Systemic Therapy or Ineligible to Receive an Anthracycline-based Treatment
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No patient enrolled as new similar study will be in system within 3 months
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-31
Primary completion date: 2017-08-17
Completion date: 2022-06-30
Clinical trial NCT03854396: Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women
Official title: A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone (DHEA, Intrarosa®) on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause
Sponsor: University of Louisville (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: due to termination of ISR by PI with agreement by grant sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-31
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: YES
IPD sharing description: De-identified raw data and other supporting materials will be made available to approved investigators. Email requests to olivia.cardenas-trowers@louisville.edu.
IPD time frame: Data will be available beginning 1 month and ending 24 months following article publication.
IPD access criteria: Available to investigators whose proposed use of the data is for individual participant data meta-analysis and has been approved by an independent review committee for this purpose. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT04032691: PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]Butanol
Official title: The Effects of Alpha-2 Adrenergic Receptor Modulation on Rates of Carbon-11 Butanol Clearance From Ventricular Cerebrospinal Fluid
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-27
Primary completion date: 2021-05-24
Completion date: 2021-05-24
Plan to share individual participant data: YES
IPD sharing description: The safety data will be shared. Data will be from the lead-in period, the on-drug period, and the washout period. Safety data include vital signs, electrocardiogram parameters, and quality of sleep measures.
IPD time frame: Available at end of study (anticipated date = 31 Dec 2020) for up to five years.
IPD access criteria: All investigators who provide a brief statement expressing a scientific interest.
Clinical trial NCT03714334: DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Official title: Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Break of stock
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-10-16
Primary completion date: 2023-04-05
Completion date: 2023-04-05
Clinical trial NCT04652245: Dymista Allergen Chamber - Onset of Action Study
Official title: Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (Dymista) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo in an Environmental Exposure Unit (EEU)
Sponsor: Viatris Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 216.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-14
Primary completion date: 2021-12-04
Completion date: 2021-12-13
Baseline population: FAS population includes all randomized patients, including subjects who received incorrect treatment, did not complete the study or did not comply to the protocol, and who were randomized but did not take any study medication
Clinical trial NCT00004935: Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Official title: Randomized Phase III Trial of Herceptin® Followed by Chemotherapy Plus Herceptin® Versus the Combination of Herceptin® and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely.
Enrollment: 175.0 (ACTUAL)
Number of arms: 2.0
Start date: 1999-08-30
Primary completion date: 2014-11-06
Completion date: 2022-03-31
Clinical trial NCT04940624: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 144.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-28
Primary completion date: 2024-04-11
Completion date: 2024-04-11
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT05001451: Study of GDX012 in Patients With MRD Positive AML
Official title: A Phase 1, Open Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, and Preliminary Antileukemic Activity of GDX012 in Patients With Minimal Residual Disease (MRD) Positive Acute Myeloid Leukemia
Sponsor: GammaDelta Therapeutics Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This was a business decision to discontinue this clinical trial. The decision is not related to the safety of the investigational product, GDX012.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-13
Primary completion date: 2022-06-03
Completion date: 2022-06-03
Plan to share individual participant data: NO
Clinical trial NCT05066698: ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
Official title: A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Sponsor: Noveome Biotherapeutics, formerly Stemnion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor undergoing financial hardships - no longer able to support trial; no safety concerns.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-27
Primary completion date: 2022-09-07
Completion date: 2022-09-07
Clinical trial NCT05489991: A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Official title: A Phase 1/2, Open-label, Multi-Center Study of Dually Armored Chimeric Antigen Receptor (CAR) T-cells (TmPSMA-02) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Sponsor: Tceleron Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was stopped Sponsor discretion. No patients were dosed.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-09-06
Primary completion date: 2023-05-03
Completion date: 2023-05-03
Clinical trial NCT04106050: Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
Official title: A Phase 1b, Randomized, Double-Blind, Parallel, Placebo- and Active-Controlled, Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 7.0
Start date: 2020-09-30
Primary completion date: 2022-01-21
Completion date: 2022-01-21
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/
Clinical trial NCT04925986: Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Official title: Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision based on data from other clinical trials
Enrollment: 9.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-02-10
Primary completion date: 2023-06-22
Completion date: 2023-10-30
Plan to share individual participant data: NO
Clinical trial NCT04409327: Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes
Official title: Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults ≥65 Years in a Nursing Home in Which ≥1 Person(s) Have Lab Confirmed COVID19
Sponsor: Restorbio Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient accrual rate
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-11
Primary completion date: 2020-12-27
Completion date: 2021-01-24
Clinical trial NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Official title: A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma.
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 37.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-06-23
Primary completion date: 2024-07-23
Completion date: 2024-07-23
Plan to share individual participant data: NO
Clinical trial NCT04534881: Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen
Official title: Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen
Sponsor: St. Louis University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: lack of recruitment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-20
Primary completion date: 2023-01-18
Completion date: 2023-01-18
Plan to share individual participant data: NO
Clinical trial NCT04948554: A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
Official title: A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants With Systemic Sclerosis
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Reasons
Enrollment: 5.0 (ACTUAL)
Number of arms: 12.0
Start date: 2023-03-10
Primary completion date: 2023-10-18
Completion date: 2023-10-18
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03777319: Spironolactone Versus Prednisolone in DMD
Official title: A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD
Sponsor: Nationwide Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inability to recruit participants.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-05
Primary completion date: 2021-09-27
Completion date: 2021-11-30
Limitations and caveats: Full enrollment into the study was unable to be obtained.
Clinical trial NCT03794154: A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions
Official title: A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE BIOEQUIVALENCE OF DULOXETINE HYDROCHLORIDE HARD GELATINOUS CAPSULE WITH DELAYED RELEASE MICROGRANULES (60 MG; PFIZER S.R.L - ARGENTINA.) COMPARED TO CYMBALTA (REGISTERED) MICROGRANULES (60 MG; ELI LILLY DO BRASIL LTDA) IN HEALTHY MALE RESEARCH SUBJECTS UNDER FED CONDITIONS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: This study has been cancelled prior to FSFV due to business reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-30
Primary completion date: 2020-06-05
Completion date: 2020-06-05
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03800290: Human Beta-2 Adrenergic Stimulation and Muscle Glucose Uptake
Official title: Targeting the Beta-2-adrenergic Pathway to Improve Skeletal Muscle Glucose Uptake in Healthy Humans
Sponsor: Maastricht University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-01
Primary completion date: 2021-04-23
Completion date: 2021-04-23